Am J Perinatol 2020; 37(05): 461-466
DOI: 10.1055/s-0039-1697675
SMFM Fellowship Series Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Association of Treatment of Chorioamnionitis with Non-Beta Lactam Antibiotics and Postcesarean Infectious Morbidity

Angelica V. Glover
1   Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
,
1   Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
,
Robert Phillips Heine
2   Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina
,
Sarah Dotters-Katz
3   Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Duke University, Durham, North Carolina
› Author Affiliations
Further Information

Publication History

09 May 2019

23 August 2019

Publication Date:
10 October 2019 (online)

Preview

Abstract

Objective Chorioamnionitis (CAM) is associated with postcesarean (CS) infectious morbidity (IM). Beta-lactam antibiotics (BLA) are used to treat CAM. It is uncertain if women who cannot receive BLA attain similar benefit from treatment of CAM with non-BLA.

Study Design Retrospective cohort of women with CAM is delivered by CS in the maternal-fetal medicine units CS registry. We compared IM in women who received BLA versus women who received non-BLA. The primary outcome was a composite of endometritis, wound complication, necrotizing fasciitis, septic pelvic thrombophlebitis, and pelvic abscess. Multivariable logistic regression estimated odds ratios for the association of non-BLA treatment with IM outcomes.

Results A total of 3,063 (93%) women received BLA, and 232 (7%) received non-BLA. Groups had similar rates of composite post-CS IM (10.6 vs. 12.1%, p = 0.5). After adjusting for confounders, treatment of CAM with non-BLA was not associated with post-CS IM (adjusted odds ratio [AOR] 1.1, 95% confidence interval [CI] 0.6–1.7), endometritis (AOR 1.1, 95% CI 0.7–1.8), or wound complications (AOR 1.2, 95% CI 0.5–3.2).

Conclusion Women with CAM who receive non-BLA and require CS may not be at increased risk of postoperative infections complications, compared to women who receive BLA.

Note

This study was presented as an oral presentation at the 2018 Infectious Disease Society of Obstetrics and Gynecology annual meeting, August 2-4, 2018, Philadelphia, PA.